MeSH term
Frequency | Condition_Probility | Female | 513 | 0.0 |
Humans | 974 | 0.0 |
Pregnancy | 5 | 0.0 |
Dose-Response Relationship, Drug | 13 | 0.0 |
Drug Administration Schedule | 2 | 0.0 |
Animals | 105 | 0.0 |
DNA Adducts | 2 | 2.0 |
DNA Damage | 23 | 2.0 |
DNA Repair | 9 | 1.0 |
Drug Resistance, Neoplasm | 5 | 0.0 |
Gene Expression | 14 | 0.0 |
Child | 71 | 0.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 2 | 2.0 |
Tumor Markers, Biological/*metabolism | 7 | 1.0 |
Adult | 298 | 0.0 |
Aged | 289 | 0.0 |
Aged, 80 and over | 135 | 1.0 |
Chemotherapy, Adjuvant | 9 | 4.0 |
Comparative Study | 96 | 0.0 |
*DNA Methylation | 17 | 2.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 31 | 1.0 |
Male | 371 | 0.0 |
Middle Aged | 346 | 0.0 |
Mutation/*genetics | 30 | 2.0 |
O(6)-Methylguanine-DNA Methyltransferase/*genetics | 3 | 9.0 |
Prognosis | 140 | 2.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Prospective Studies | 8 | 0.0 |
Protein p53/*genetics | 70 | 43.0 |
Radiation Dosage | 9 | 9.0 |
Radiotherapy, Adjuvant | 2 | 2.0 |
Research Support, Non-U.S. Gov't | 632 | 0.0 |
Survival Rate | 40 | 1.0 |
In Situ Hybridization, Fluorescence | 51 | 1.0 |
Mice | 56 | 0.0 |
Microsatellite Repeats | 56 | 4.0 |
Molecular Sequence Data | 91 | 0.0 |
Rats | 8 | 0.0 |
Sequence Analysis, DNA | 26 | 0.0 |
*Chromosomes, Human | 7 | 10.0 |
*Loss of Heterozygosity | 47 | 12.0 |
*Mutation | 112 | 2.0 |
Ovarian Neoplasms/*genetics/pathology | 7 | 8.0 |
Cell Division/drug effects | 5 | 0.0 |
DNA, Neoplasm/metabolism | 4 | 2.0 |
Drug Screening Assays, Antitumor | 3 | 0.0 |
Lung Neoplasms/*drug therapy/pathology | 2 | 6.0 |
Protein p53/*metabolism | 32 | 5.0 |
Tumor Cells, Cultured | 110 | 0.0 |
Bladder/pathology | 2 | 13.0 |
DNA Fragmentation | 2 | 0.0 |
DNA, Neoplasm/analysis | 51 | 6.0 |
Dissection | 5 | 23.0 |
Genes, p53 | 82 | 17.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Kinetics | 5 | 0.0 |
Micromanipulation | 3 | 17.0 |
Mitotic Index | 6 | 3.0 |
Mucous Membrane/pathology | 2 | 5.0 |
Neoplasm Invasiveness | 19 | 1.0 |
Polymerase Chain Reaction | 183 | 1.0 |
Cell Cycle/radiation effects | 5 | 17.0 |
Cell Division/radiation effects | 7 | 14.0 |
Cell Line | 36 | 0.0 |
Diploidy | 3 | 2.0 |
Lung | 2 | 2.0 |
Research Support, U.S. Gov't, P.H.S. | 173 | 0.0 |
Time Factors | 38 | 0.0 |
X-Rays | 9 | 8.0 |
Adolescent | 87 | 0.0 |
Astrocytoma/*genetics/pathology | 7 | 30.0 |
Clone Cells | 7 | 0.0 |
DNA Mutational Analysis | 91 | 2.0 |
Dosage Compensation (Genetics) | 2 | 1.0 |
Genetic Markers | 43 | 1.0 |
Loss of Heterozygosity | 91 | 11.0 |
Methylation | 2 | 0.0 |
Protein p53/genetics/metabolism | 11 | 11.0 |
Receptors, Androgen/genetics/metabolism | 2 | 14.0 |
Antineoplastic Agents/*pharmacology | 5 | 0.0 |
Cell Survival/drug effects | 4 | 0.0 |
Colonic Neoplasms | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
Genes, Reporter | 3 | 0.0 |
Genes, p53/*drug effects | 2 | 28.0 |
Protein p53/genetics | 30 | 18.0 |
Transfection | 18 | 0.0 |
Child, Preschool | 47 | 0.0 |
Gene Amplification | 26 | 3.0 |
*Genes, p53 | 159 | 32.0 |
Genotype | 41 | 0.0 |
Germ-Line Mutation/*genetics | 6 | 3.0 |
Immunohistochemistry/methods | 3 | 0.0 |
Infant | 29 | 0.0 |
Li-Fraumeni Syndrome/*genetics | 11 | 64.0 |
Osteosarcoma/genetics | 3 | 25.0 |
Pedigree | 27 | 0.0 |
Phenotype | 19 | 0.0 |
Polymorphism, Single-Stranded Conformational | 80 | 3.0 |
Flow Cytometry | 33 | 0.0 |
G2 Phase | 2 | 1.0 |
*Gamma Rays | 3 | 6.0 |
Mutation | 145 | 1.0 |
Radiation-Sensitizing Agents/*pharmacology | 5 | 17.0 |
Chromosomes, Human, Pair 17/*genetics | 22 | 13.0 |
DNA/*genetics | 2 | 0.0 |
Models, Genetic | 9 | 0.0 |
Epithelial Cells/pathology | 3 | 3.0 |
Exons | 50 | 1.0 |
Genetic Predisposition to Disease | 20 | 0.0 |
Immunocompetence | 2 | 4.0 |
Papillomavirus, Human/genetics/*isolation & purification | 2 | 13.0 |
Polymorphism, Single Nucleotide | 3 | 0.0 |
Prevalence | 6 | 0.0 |
Risk Factors | 35 | 0.0 |
Adenocarcinoma/*genetics/pathology | 13 | 13.0 |
Biopsy | 8 | 0.0 |
Liver Neoplasms/*genetics/pathology | 4 | 16.0 |
*Microsatellite Repeats | 16 | 7.0 |
Cervix Neoplasms/*genetics/pathology/virology | 2 | 22.0 |
DNA, Viral/analysis | 6 | 1.0 |
*Exons | 4 | 1.0 |
Genes, p53/*genetics | 132 | 39.0 |
*Polymorphism, Genetic | 17 | 0.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Case-Control Studies | 22 | 0.0 |
Gene Frequency | 18 | 0.0 |
*Genetic Predisposition to Disease | 14 | 1.0 |
Haplotypes | 3 | 0.0 |
Polymorphism, Single Nucleotide/genetics | 2 | 0.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 4 | 1.0 |
Base Sequence | 103 | 0.0 |
DNA Primers | 33 | 0.0 |
DNA Repair/*genetics | 4 | 1.0 |
Infant, Newborn | 9 | 0.0 |
Immunohistochemistry | 105 | 0.0 |
Likelihood Functions | 2 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 24 | 0.0 |
Risk | 6 | 0.0 |
Sensitivity and Specificity | 16 | 0.0 |
Treatment Outcome | 23 | 0.0 |
Apoptosis | 22 | 1.0 |
Caffeine/pharmacology | 2 | 2.0 |
Cell Cycle/*radiation effects | 4 | 25.0 |
Cell Line, Tumor | 19 | 0.0 |
DNA/metabolism | 5 | 0.0 |
*Radiation, Ionizing | 2 | 8.0 |
Blotting, Western | 25 | 0.0 |
Cell Cycle | 12 | 1.0 |
Cell Death | 2 | 0.0 |
Cell Division | 22 | 0.0 |
Cell Survival | 9 | 0.0 |
Dose-Response Relationship, Radiation | 26 | 7.0 |
G1 Phase | 7 | 2.0 |
Lymphocytes/*radiation effects | 3 | 27.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
*Oxidative Stress | 3 | 1.0 |
Signal Transduction | 14 | 0.0 |
BRCA1 Protein/genetics/metabolism | 2 | 15.0 |
DNA Repair/genetics | 2 | 1.0 |
Genes, BRCA1 | 6 | 3.0 |
Genes, BRCA2 | 4 | 3.0 |
*Germ-Line Mutation | 12 | 2.0 |
Polymorphism, Genetic | 25 | 0.0 |
Variation (Genetics) | 6 | 0.0 |
Apoptosis/*genetics | 2 | 0.0 |
Cyclin-Dependent Kinases/genetics | 7 | 12.0 |
DNA-Binding Proteins/genetics | 10 | 1.0 |
Gene Expression Profiling/*statistics & numerical data | 3 | 60.0 |
*Genes, cdc | 2 | 9.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Neoplasm Proteins/genetics | 22 | 4.0 |
Polymerase Chain Reaction/methods | 19 | 1.0 |
*Proto-Oncogene Proteins | 12 | 0.0 |
*Saccharomyces cerevisiae Proteins | 5 | 0.0 |
Transcription Factors/genetics | 13 | 1.0 |
*Apoptosis | 6 | 0.0 |
Cell Movement | 2 | 0.0 |
Cisplatin/pharmacology | 3 | 1.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Microscopy, Fluorescence | 3 | 0.0 |
Nuclear Proteins/metabolism | 4 | 0.0 |
Protein Binding | 7 | 0.0 |
Protein Isoforms | 3 | 0.0 |
Protein p53/metabolism | 40 | 6.0 |
Transcription, Genetic | 10 | 0.0 |
Up-Regulation | 8 | 0.0 |
Adenoviridae/genetics | 4 | 0.0 |
Gene Therapy/*methods | 3 | 0.0 |
Genes, Tumor Suppressor/physiology | 4 | 8.0 |
Loss of Heterozygosity/genetics | 8 | 6.0 |
Survival Analysis | 56 | 2.0 |
Cytoskeletal Proteins/genetics | 3 | 4.0 |
*Genes, Tumor Suppressor | 30 | 2.0 |
Genes, p16 | 11 | 11.0 |
Phosphoric Monoester Hydrolases/genetics | 12 | 16.0 |
Ploidies | 13 | 4.0 |
Proto-Oncogene Proteins/genetics | 25 | 4.0 |
*Trans-Activators | 3 | 0.0 |
Tumor Suppressor Proteins/genetics | 10 | 14.0 |
Breast Neoplasms/*genetics | 29 | 3.0 |
Genetic Screening | 6 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 47 | 0.0 |
Tumor Markers, Biological | 9 | 2.0 |
Adenoma/*genetics | 3 | 3.0 |
Chi-Square Distribution | 5 | 0.0 |
Colorectal Neoplasms/*genetics | 13 | 6.0 |
Point Mutation/*genetics | 6 | 2.0 |
Alleles | 67 | 0.0 |
Amino Acid Substitution | 11 | 0.0 |
Arginine/genetics | 6 | 3.0 |
Codon/genetics | 10 | 3.0 |
DNA, Neoplasm/chemistry/genetics | 10 | 8.0 |
Disease-Free Survival | 31 | 3.0 |
Protein p53/biosynthesis/*genetics | 4 | 26.0 |
Severity of Illness Index | 2 | 0.0 |
World Health Organization | 2 | 2.0 |
Cell Line, Transformed | 9 | 0.0 |
Cyclins/*metabolism | 5 | 1.0 |
DNA, Complementary/metabolism | 3 | 0.0 |
Protein p53/*genetics/physiology | 5 | 38.0 |
Radiation-Protective Agents/*therapeutic use | 2 | 66.0 |
Serine/metabolism | 2 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 4 | 2.0 |
DNA/analysis | 5 | 0.0 |
*DNA-Binding Proteins | 7 | 0.0 |
Genes, ras | 12 | 4.0 |
Proteins/genetics | 6 | 0.0 |
Algorithms | 4 | 1.0 |
Codon | 12 | 2.0 |
DNA Mutational Analysis/*methods | 5 | 3.0 |
Introns | 7 | 0.0 |
Mutation, Missense | 11 | 1.0 |
Oligonucleotide Array Sequence Analysis | 10 | 0.0 |
Bladder Neoplasms/*genetics | 15 | 18.0 |
Carcinoma, Transitional Cell/*genetics | 4 | 12.0 |
Chromosome Mapping | 51 | 0.0 |
*Chromosomes, Human, Pair 17 | 49 | 9.0 |
Disease Progression | 42 | 1.0 |
English Abstract | 29 | 0.0 |
Gene Deletion | 36 | 1.0 |
Loss of Heterozygosity/*genetics | 19 | 21.0 |
Microsatellite Repeats/genetics | 23 | 6.0 |
Cytoplasm/chemistry | 2 | 1.0 |
Proteins/*metabolism | 3 | 0.0 |
*Chromosomes, Human, Pair 2 | 3 | 1.0 |
*Chromosomes, Human, Pair 7 | 2 | 0.0 |
Cytogenetic Analysis | 9 | 7.0 |
Gene Expression Regulation | 5 | 0.0 |
Leukemia/*genetics | 4 | 3.0 |
Protein-Serine-Threonine Kinases/*genetics/metabolism | 5 | 8.0 |
*Translocation, Genetic | 5 | 0.0 |
Lasers | 4 | 3.0 |
Neoplasms/*genetics | 14 | 5.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Sequence Analysis, DNA/methods | 2 | 2.0 |
*Evolution, Molecular | 2 | 0.0 |
Gene Rearrangement | 6 | 1.0 |
Translocation, Genetic | 9 | 1.0 |
Apoptosis/radiation effects | 4 | 10.0 |
Cell Hypoxia | 3 | 1.0 |
Mice, Inbred BALB C | 7 | 0.0 |
Mice, Nude | 18 | 0.0 |
Micronucleus Tests | 5 | 10.0 |
Neoplasm Transplantation | 12 | 1.0 |
Point Mutation | 22 | 1.0 |
Radiation Tolerance/*genetics | 2 | 3.0 |
*Membrane Proteins | 3 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Trans-Activation (Genetics) | 4 | 0.0 |
Analysis of Variance | 8 | 0.0 |
Bladder Neoplasms/genetics/*metabolism | 2 | 5.0 |
Blotting, Northern | 9 | 0.0 |
Immunoenzyme Techniques | 17 | 0.0 |
Neoplasm Staging | 67 | 2.0 |
Predictive Value of Tests | 15 | 0.0 |
RNA, Messenger/metabolism | 7 | 0.0 |
Apoptosis/*radiation effects | 4 | 9.0 |
Caspases/metabolism | 3 | 0.0 |
Cell Survival/radiation effects | 7 | 8.0 |
Colony-Forming Units Assay | 4 | 0.0 |
Breast Neoplasms/epidemiology/*genetics | 3 | 2.0 |
Sweden/epidemiology | 2 | 1.0 |
Carcinoma, Squamous Cell/*genetics | 12 | 6.0 |
Chromosomes, Human, Pair 17/genetics | 17 | 9.0 |
Chromosomes, Human, Pair 3/genetics | 2 | 1.0 |
DNA, Neoplasm/*genetics | 16 | 6.0 |
India | 3 | 0.0 |
Lung Neoplasms/*genetics | 13 | 5.0 |
Genes, p53/genetics | 54 | 24.0 |
Genes, ras/genetics | 7 | 6.0 |
Lymph Nodes/pathology | 7 | 2.0 |
DNA, Neoplasm/genetics | 46 | 5.0 |
Neoplasm Recurrence, Local/*genetics | 3 | 18.0 |
Cyclins/*genetics | 2 | 1.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
DNA Replication | 4 | 1.0 |
*Occupational Exposure | 3 | 2.0 |
Apoptosis/genetics | 11 | 4.0 |
Cell Cycle/genetics | 3 | 2.0 |
Protein p53/*physiology | 8 | 6.0 |
DNA, Complementary | 2 | 0.0 |
DNA, Neoplasm/*analysis | 9 | 4.0 |
Gene Expression Profiling | 7 | 0.0 |
*Gene Expression Regulation, Neoplastic | 26 | 1.0 |
*Allelic Imbalance | 3 | 23.0 |
Breast Neoplasms/*genetics/pathology | 15 | 6.0 |
Carcinoma in Situ/*genetics/pathology | 6 | 40.0 |
Carcinoma, Ductal, Breast/*genetics/pathology | 4 | 15.0 |
Metaplasia | 2 | 2.0 |
Alcohol Drinking/adverse effects | 2 | 4.0 |
Esophageal Neoplasms/etiology/*genetics | 3 | 60.0 |
Protein p53/analysis | 22 | 7.0 |
Smoking/adverse effects | 4 | 1.0 |
Antigens, CD/*genetics | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 9 | 1.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
*Gene Deletion | 27 | 3.0 |
Vincristine/administration & dosage | 3 | 1.0 |
*Cell Cycle Proteins | 8 | 0.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
*Nuclear Proteins | 38 | 2.0 |
Phosphorylation | 4 | 0.0 |
Aneuploidy | 9 | 4.0 |
Cells, Cultured/radiation effects | 3 | 25.0 |
Chromosome Aberrations | 27 | 4.0 |
*Chromosome Breakage | 2 | 5.0 |
Li-Fraumeni Syndrome/*genetics/pathology | 4 | 80.0 |
Mice, Knockout | 3 | 0.0 |
Species Specificity | 4 | 0.0 |
Brain Neoplasms/*genetics/metabolism/pathology | 2 | 8.0 |
Protein p53/genetics/*metabolism | 8 | 4.0 |
*Genetic Markers | 5 | 1.0 |
Neoplasm Metastasis/*genetics | 2 | 3.0 |
*Alternative Splicing | 3 | 0.0 |
Breast Neoplasms/*genetics/metabolism | 3 | 2.0 |
Bladder Neoplasms/*genetics/metabolism | 2 | 14.0 |
Carcinoma/*genetics/metabolism | 3 | 10.0 |
Cells, Cultured | 19 | 0.0 |
Phosphoproteins/genetics | 2 | 1.0 |
Carcinoma/*genetics/pathology | 11 | 17.0 |
DNA Methylation | 14 | 2.0 |
*Genes, p16 | 5 | 5.0 |
Promoter Regions (Genetics) | 6 | 0.0 |
Brain Neoplasms/*genetics/pathology | 9 | 13.0 |
Chromosome Deletion | 25 | 3.0 |
Chromosomes, Human, Pair 1/*genetics | 5 | 2.0 |
Molecular Biology | 8 | 3.0 |
Neoplasm Proteins/*genetics | 22 | 2.0 |
Oligodendroglioma/*genetics/pathology | 2 | 16.0 |
Protein p16/genetics | 11 | 12.0 |
Receptor, Epidermal Growth Factor/genetics | 13 | 11.0 |
Tumor Markers, Biological/genetics | 4 | 4.0 |
Bladder Neoplasms/*genetics/metabolism/pathology | 2 | 14.0 |
Cyclins/genetics/metabolism | 2 | 3.0 |
Follow-Up Studies | 19 | 0.0 |
Mutation/genetics | 22 | 2.0 |
Neoplasm Proteins/genetics/metabolism | 2 | 1.0 |
Paraffin Embedding | 6 | 2.0 |
Protein p53/*genetics/*metabolism | 3 | 21.0 |
Amino Acid Substitution/genetics | 5 | 1.0 |
Automation | 2 | 3.0 |
Conserved Sequence/genetics | 2 | 1.0 |
Databases, Nucleic Acid | 2 | 5.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Zinc/metabolism | 2 | 2.0 |
Genes, Retinoblastoma | 8 | 8.0 |
Minisatellite Repeats | 2 | 1.0 |
Neoplasms, Radiation-Induced/*genetics | 3 | 11.0 |
Radiation, Ionizing | 3 | 2.0 |
Binding Sites | 5 | 0.0 |
Cell Nucleus/metabolism | 7 | 0.0 |
Chromatin/metabolism | 2 | 0.0 |
DNA/*radiation effects | 3 | 10.0 |
*DNA Damage | 12 | 2.0 |
*DNA Repair | 5 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 2 | 0.0 |
Space Flight | 2 | 18.0 |
Thymidine Kinase/*genetics | 2 | 4.0 |
Gene Silencing | 20 | 6.0 |
Genes, p53/*physiology | 6 | 13.0 |
Homozygote | 11 | 0.0 |
Retinoblastoma Protein/*genetics/metabolism | 2 | 28.0 |
Signal Transduction/*genetics | 4 | 3.0 |
Retrospective Studies | 17 | 0.0 |
Gamma Rays | 13 | 5.0 |
Immunoglobulin Variable Region/genetics | 2 | 1.0 |
Immunoglobulins, Heavy-Chain/genetics | 2 | 1.0 |
Leukemia, B-Cell, Chronic/*genetics | 5 | 13.0 |
Annexin A5/pharmacology | 3 | 8.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Protein p53/biosynthesis | 8 | 5.0 |
DNA Replication/genetics | 3 | 5.0 |
Mutation, Missense/genetics | 2 | 1.0 |
Point Mutation/genetics | 6 | 2.0 |
*Protein-Serine-Threonine Kinases | 7 | 0.0 |
Carcinoma, Non-Small-Cell Lung/*genetics | 2 | 2.0 |
Chromosomes, Human, Pair 3/*genetics | 5 | 2.0 |
Chromosomes, Human, Pair 5/*genetics | 3 | 3.0 |
Chromosomes, Human, Pair 9/*genetics | 6 | 5.0 |
Blotting, Southern | 19 | 0.0 |
DNA-Binding Proteins/*genetics | 10 | 0.0 |
Doxorubicin/therapeutic use | 2 | 3.0 |
Immunophenotyping | 7 | 0.0 |
Proto-Oncogene Proteins/*genetics | 14 | 1.0 |
Transcription Factors/*genetics | 17 | 0.0 |
Vincristine/therapeutic use | 2 | 5.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 8 | 12.0 |
*Gene Expression Profiling | 3 | 0.0 |
Genes, Tumor Suppressor | 29 | 3.0 |
Tumor Markers, Biological/*analysis | 9 | 0.0 |
Cell Transformation, Neoplastic | 9 | 1.0 |
Karyotyping | 42 | 2.0 |
Saccharomyces cerevisiae/genetics | 2 | 0.0 |
*Lasers | 2 | 9.0 |
Cell Division/genetics | 4 | 1.0 |
Cervix Neoplasms/genetics/*pathology | 2 | 66.0 |
Genetic Vectors/genetics | 2 | 0.0 |
Protein p53/physiology | 5 | 6.0 |
Retinoblastoma Protein/*genetics | 6 | 13.0 |
Ovarian Neoplasms/*genetics | 17 | 4.0 |
Protein p53/analysis/*biosynthesis | 5 | 22.0 |
Proto-Oncogene Proteins/analysis/*biosynthesis | 2 | 8.0 |
Proto-Oncogene Proteins c-bcl-2/analysis/*biosynthesis | 2 | 18.0 |
Colonic Neoplasms/genetics | 4 | 6.0 |
DNA, Complementary/genetics | 5 | 0.0 |
*Mutation, Missense | 5 | 0.0 |
Protein Kinases/*genetics/metabolism | 2 | 8.0 |
Multivariate Analysis | 12 | 0.0 |
Myelodysplastic Syndromes/*genetics/pathology | 2 | 13.0 |
Multigene Family | 4 | 0.0 |
*Aneuploidy | 3 | 3.0 |
Cyclins/*biosynthesis/genetics | 2 | 5.0 |
*Diploidy | 2 | 9.0 |
Life Tables | 3 | 1.0 |
Neoplasm Proteins/*biosynthesis/genetics | 2 | 1.0 |
Protein p53/*biosynthesis | 7 | 5.0 |
Radiation Tolerance | 5 | 5.0 |
*Genes, ras | 8 | 3.0 |
Meningioma/*genetics | 3 | 9.0 |
Phosphoric Monoester Hydrolases/*genetics | 7 | 3.0 |
*Tumor Suppressor Proteins | 16 | 1.0 |
Carcinogens | 3 | 3.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Smoking/*adverse effects | 4 | 1.0 |
Neoplasm Metastasis | 9 | 0.0 |
Proportional Hazards Models | 12 | 1.0 |
Tumor Markers, Biological/metabolism | 5 | 1.0 |
Bleomycin/pharmacology | 4 | 14.0 |
Cyclins/genetics | 7 | 4.0 |
Gene Expression Regulation, Neoplastic/*radiation effects | 2 | 9.0 |
Chromosomes, Human, Pair 1 | 6 | 2.0 |
Models, Biological | 5 | 0.0 |
Neoplasms/metabolism | 2 | 2.0 |
Chromosomes, Human, Pair 10 | 3 | 2.0 |
Chromosomes, Human, Pair 19 | 2 | 1.0 |
Genes, p16/genetics | 5 | 22.0 |
*Genetic Heterogeneity | 6 | 4.0 |
DNA-Binding Proteins/*genetics/metabolism | 3 | 0.0 |
Transcription Factors/*genetics/metabolism | 2 | 0.0 |
Treatment Failure | 2 | 0.0 |
*Acid Anhydride Hydrolases | 2 | 0.0 |
BRCA2 Protein | 14 | 2.0 |
Chromosomes, Human, Pair 13 | 9 | 7.0 |
*Chromosomes, Human, Pair 3 | 7 | 1.0 |
*Chromosomes, Human, Pair 9 | 5 | 1.0 |
Astrocytoma/*genetics | 5 | 11.0 |
Brain Neoplasms/*genetics | 9 | 6.0 |
DNA Primers/chemistry | 10 | 0.0 |
*Point Mutation | 21 | 1.0 |
Promoter Regions (Genetics)/*genetics | 6 | 0.0 |
*Antigens, Nuclear | 2 | 1.0 |
*DNA Helicases | 2 | 0.0 |
DNA Repair/*physiology | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/*physiology | 3 | 1.0 |
Genes, p53/physiology | 3 | 11.0 |
Introns/genetics | 5 | 0.0 |
Mutation/physiology | 3 | 2.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Chromosome Aberrations/genetics | 6 | 5.0 |
Chromosomes, Human, Pair 11/*genetics | 3 | 1.0 |
Chromosomes, Human, Pair 14/genetics | 2 | 2.0 |
Chromosomes, Human, Pair 7/*genetics | 2 | 1.0 |
Chromosomes, Human, Pair 8/genetics | 2 | 2.0 |
Gene Dosage | 7 | 1.0 |
Genes, myc | 7 | 2.0 |
Karyotyping/methods | 4 | 14.0 |
*Proto-Oncogenes | 4 | 0.0 |
*Transcription Factors | 3 | 0.0 |
Genes, ras/*genetics | 12 | 12.0 |
Lung Neoplasms/etiology/*genetics | 3 | 11.0 |
Smoking/adverse effects/genetics | 2 | 20.0 |
BRCA2 Protein/genetics | 2 | 5.0 |
Precancerous Conditions | 2 | 11.0 |
Protein-Serine-Threonine Kinases/genetics | 4 | 3.0 |
RNA/metabolism | 2 | 0.0 |
Astrocytoma/*genetics/metabolism/pathology | 2 | 16.0 |
Protein p53/*genetics/metabolism | 6 | 15.0 |
Colonic Neoplasms/*genetics/pathology | 4 | 8.0 |
Nucleic Acid Denaturation | 5 | 5.0 |
Cell Culture Techniques/methods | 4 | 1.0 |
Oncogene Proteins, Fusion/*genetics | 2 | 1.0 |
Logistic Models | 5 | 0.0 |
Odds Ratio | 6 | 0.0 |
Questionnaires | 2 | 0.0 |
Tumor Markers, Biological/*genetics | 8 | 7.0 |
Cadherins/genetics | 2 | 3.0 |
Carrier Proteins/genetics | 3 | 0.0 |
CpG Islands | 6 | 2.0 |
*Promoter Regions (Genetics) | 4 | 0.0 |
Heterozygote | 39 | 1.0 |
Protein p53/analysis/*genetics | 7 | 53.0 |
Cell Nucleus/*metabolism | 2 | 0.0 |
Genes, bcl-2 | 5 | 4.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 2 | 1.0 |
Survivors | 2 | 2.0 |
Antigens, Nuclear | 2 | 1.0 |
Ki-67 Antigen | 4 | 1.0 |
Neurofibromin 1 | 2 | 1.0 |
Nuclear Proteins/genetics | 5 | 1.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 2 | 0.0 |
Age Distribution | 4 | 1.0 |
Age of Onset | 7 | 0.0 |
Penetrance | 3 | 2.0 |
Disease Susceptibility | 5 | 0.0 |
Colorectal Neoplasms/*epidemiology/*genetics | 2 | 40.0 |
Genes, Tumor Suppressor/genetics | 13 | 7.0 |
Oncogenes/genetics | 4 | 5.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Protease Inhibitors/*pharmacology | 2 | 4.0 |
Ultraviolet Rays | 4 | 0.0 |
G2 Phase/*drug effects | 2 | 6.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
*Alleles | 23 | 1.0 |
Chromosomes, Human, Pair 9/genetics | 10 | 8.0 |
DNA, Neoplasm/analysis/genetics | 3 | 3.0 |
Neoplasm Metastasis/*genetics/pathology | 2 | 20.0 |
Polymorphism, Genetic/genetics | 4 | 0.0 |
Anemia, Refractory, with Excess of Blasts/genetics | 2 | 22.0 |
Chromosome Banding | 12 | 1.0 |
Myelodysplastic Syndromes/*genetics | 5 | 7.0 |
Oncogenes | 8 | 3.0 |
Translocation, Genetic/genetics | 4 | 4.0 |
Cisplatin/administration & dosage | 4 | 1.0 |
Combined Modality Therapy | 5 | 0.0 |
Age Factors | 12 | 0.0 |
Genetic Counseling | 2 | 1.0 |
*Dyes | 2 | 33.0 |
In Situ Hybridization | 7 | 0.0 |
Adrenal Gland Neoplasms/*genetics/metabolism | 2 | 33.0 |
Frameshift Mutation | 8 | 2.0 |
Gene Expression Regulation, Neoplastic/genetics | 4 | 2.0 |
Nuclear Proteins/biosynthesis/*genetics | 2 | 5.0 |
RNA, Neoplasm/genetics | 4 | 1.0 |
BRCA1 Protein/*genetics | 5 | 2.0 |
Cyclin D1/analysis | 2 | 5.0 |
DNA Mutational Analysis/methods | 6 | 2.0 |
Family Health | 9 | 0.0 |
*Heterozygote | 6 | 1.0 |
Ki-67 Antigen/analysis | 7 | 2.0 |
Receptor, erbB-2/analysis | 2 | 2.0 |
Receptors, Estrogen/analysis | 7 | 2.0 |
Receptors, Progesterone/analysis | 6 | 2.0 |
Registries | 2 | 0.0 |
*Chromosome Aberrations | 38 | 6.0 |
Laryngeal Neoplasms/*genetics/pathology | 2 | 18.0 |
Microsatellite Repeats/*genetics | 9 | 3.0 |
*Nucleoside-Diphosphate Kinase | 5 | 7.0 |
Breast Neoplasms/*genetics/metabolism/pathology | 2 | 3.0 |
Carcinoma, Ductal, Breast/genetics | 2 | 11.0 |
Lymphatic Metastasis | 15 | 1.0 |
Receptors, Estrogen/metabolism | 3 | 1.0 |
Statistics, Nonparametric | 2 | 0.0 |
Genes, BRCA1/*genetics | 7 | 3.0 |
Italy/epidemiology | 2 | 0.0 |
Proto-Oncogene Proteins/analysis | 5 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 3 | 1.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Protein p53/*biosynthesis/genetics | 2 | 5.0 |
Molecular Biology/methods | 4 | 14.0 |
Neurofibromatosis 1/*genetics | 3 | 1.0 |
Protein p16/genetics/metabolism | 3 | 11.0 |
Genetic Techniques | 3 | 3.0 |
Precancerous Conditions/*genetics/pathology | 3 | 15.0 |
Genes, BRCA1/genetics | 3 | 4.0 |
Leukemia, Myelocytic, Acute/*genetics | 3 | 2.0 |
Ovarian Neoplasms/genetics | 4 | 2.0 |
Protein p53/chemistry/genetics/metabolism | 2 | 40.0 |
Brain Neoplasms/*genetics/metabolism | 2 | 7.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
Glioblastoma/*genetics/metabolism | 2 | 16.0 |
Sex Factors | 7 | 0.0 |
Neoplasm Proteins/analysis/genetics | 2 | 8.0 |
Nerve Tissue Proteins/analysis/genetics | 2 | 33.0 |
CHO Cells | 3 | 0.0 |
Genome | 2 | 0.0 |
Glutathione Transferase/genetics | 5 | 1.0 |
Hamsters | 8 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Protein p53/biosynthesis/genetics | 5 | 10.0 |
Transfection/*methods | 2 | 3.0 |
*Gene Amplification | 9 | 2.0 |
Proteins/*genetics | 6 | 0.0 |
p14ARF Protein | 7 | 8.0 |
Carcinoma, Ductal, Breast/*genetics | 2 | 8.0 |
Cell Count | 3 | 0.0 |
Adenocarcinoma/*genetics/metabolism | 2 | 5.0 |
Neoplasm Proteins/metabolism | 7 | 1.0 |
Gene Expression Regulation, Neoplastic/*genetics | 7 | 3.0 |
Neoplasm Proteins/biosynthesis/*genetics | 3 | 3.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Bladder Neoplasms/*genetics/pathology | 9 | 23.0 |
Carcinoma in Situ/genetics | 5 | 25.0 |
Carcinoma, Transitional Cell/*genetics/pathology | 6 | 33.0 |
China/epidemiology | 3 | 1.0 |
Esophageal Neoplasms/*genetics | 9 | 12.0 |
Proto-Oncogene Proteins/*genetics/metabolism | 3 | 2.0 |
Base Sequence/genetics | 3 | 0.0 |
Nucleic Acid Hybridization | 14 | 0.0 |
DNA, Neoplasm/genetics/metabolism | 3 | 3.0 |
Zinc Fingers/genetics | 2 | 1.0 |
Papillomavirus, Human/isolation & purification | 4 | 16.0 |
Brazil | 4 | 1.0 |
*Genetics, Population | 3 | 0.0 |
*Haplotypes | 2 | 0.0 |
Indians, South American/*genetics | 2 | 3.0 |
*Variation (Genetics) | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 12 | 2.0 |
*DNA Mutational Analysis | 4 | 2.0 |
Drug Resistance, Neoplasm/genetics | 4 | 5.0 |
Acute Disease | 9 | 0.0 |
Chromosome Disorders | 5 | 1.0 |
Gene Amplification/*genetics | 5 | 4.0 |
*Gene Duplication | 2 | 1.0 |
Nucleic Acid Hybridization/methods | 2 | 2.0 |
Recurrence | 6 | 0.0 |
*Chromosome Mapping | 10 | 0.0 |
Gene Library | 3 | 0.0 |
*In Situ Hybridization, Fluorescence | 2 | 1.0 |
Metaphase | 3 | 2.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 2 | 1.0 |
Oligonucleotides, Antisense/pharmacology | 3 | 1.0 |
Tumor Cells, Cultured/radiation effects | 3 | 7.0 |
Incidence | 5 | 0.0 |
Risk Assessment | 7 | 0.0 |
Sampling Studies | 2 | 1.0 |
Cyclins/metabolism | 6 | 1.0 |
Interphase/drug effects | 2 | 7.0 |
Skin/cytology | 2 | 1.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 2 | 2.0 |
Protein p53/genetics/physiology | 2 | 8.0 |
DNA, Neoplasm/chemistry | 2 | 9.0 |
Thymidine/metabolism | 2 | 0.0 |
Neoplasm Proteins/*analysis | 3 | 0.0 |
Stomach Neoplasms/*genetics/pathology/surgery | 3 | 37.0 |
Flounder/*genetics | 2 | 66.0 |
Mutagens/*toxicity | 2 | 1.0 |
Yeasts/genetics | 2 | 2.0 |
Actins/genetics | 2 | 1.0 |
Bone Neoplasms/*genetics | 5 | 11.0 |
Osteosarcoma/*genetics | 7 | 22.0 |
Sarcoma/*genetics | 5 | 14.0 |
Telomere/*genetics | 2 | 5.0 |
Carcinoma, Squamous Cell/genetics | 6 | 11.0 |
Cervix Neoplasms/*genetics | 3 | 11.0 |
Chromosome Aberrations/*genetics | 7 | 5.0 |
Uterine Neoplasms/*genetics | 3 | 7.0 |
Cell Communication/*physiology | 2 | 3.0 |
Dogs | 4 | 0.0 |
Mutagenesis/genetics | 2 | 5.0 |
Papillomavirus, Human/*genetics | 2 | 2.0 |
Proline/genetics | 4 | 7.0 |
Tumor Virus Infections/complications/virology | 2 | 100.0 |
Genetic Markers/*genetics | 2 | 1.0 |
Cohort Studies | 7 | 0.0 |
Conserved Sequence/*genetics | 2 | 3.0 |
Neoplastic Syndromes, Hereditary/*genetics | 2 | 4.0 |
Fatal Outcome | 2 | 0.0 |
Genes, erbB-1/genetics | 4 | 23.0 |
Cell Transformation, Neoplastic/*genetics/pathology | 4 | 16.0 |
Exons/genetics | 16 | 1.0 |
Genes, Neurofibromatosis 1/genetics | 2 | 15.0 |
Chromosomes, Human, Pair 18/genetics | 3 | 6.0 |
Magnetic Resonance Imaging | 5 | 0.0 |
Tomography, X-Ray Computed | 4 | 0.0 |
Cyclins/biosynthesis | 3 | 3.0 |
Phosphorylation/radiation effects | 2 | 6.0 |
Skin Neoplasms/*genetics | 4 | 3.0 |
Germ-Line Mutation | 10 | 2.0 |
Introns/*genetics | 6 | 3.0 |
Sequence Deletion | 16 | 0.0 |
Gene Frequency/*genetics | 2 | 1.0 |
Quality Control | 4 | 2.0 |
Tandem Repeat Sequences/*genetics | 2 | 2.0 |
Genes, Retinoblastoma/genetics | 9 | 29.0 |
DNA Replication/*genetics | 3 | 5.0 |
Chromosomes, Human | 3 | 5.0 |
Apoptosis/drug effects | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Necrosis | 2 | 0.0 |
*Gene Therapy | 6 | 1.0 |
Neovascularization, Pathologic/etiology | 2 | 9.0 |
Telomerase/metabolism | 2 | 3.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Antibiotics, Antineoplastic/*pharmacology | 3 | 2.0 |
Cell Cycle/drug effects/radiation effects | 2 | 10.0 |
Cell Survival/drug effects/radiation effects | 6 | 14.0 |
Isoenzymes/genetics | 3 | 0.0 |
Endometriosis/*genetics/pathology | 2 | 40.0 |
Radiation Tolerance/*drug effects | 4 | 23.0 |
Radiation-Sensitizing Agents/pharmacology | 3 | 13.0 |
DNA/genetics | 3 | 0.0 |
DNA Primers/genetics | 4 | 0.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
*Oncogenes | 5 | 1.0 |
*Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Soft Tissue Neoplasms/*genetics | 2 | 7.0 |
Alternative Splicing | 2 | 0.0 |
Neoplasm Proteins/*genetics/metabolism | 4 | 2.0 |
Postoperative Period | 2 | 0.0 |
Neoplasms, Multiple Primary/*genetics | 7 | 17.0 |
Pancreatic Neoplasms/*genetics | 3 | 3.0 |
Amino Acid Sequence | 14 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Genome, Human | 4 | 0.0 |
Sequence Homology | 2 | 0.0 |
Nuclear Proteins/analysis | 3 | 1.0 |
Carcinoma, Squamous Cell/epidemiology/*genetics | 2 | 11.0 |
Life Style | 2 | 1.0 |
*Chromosomes, Human, Pair 12 | 5 | 1.0 |
Colon/pathology | 3 | 7.0 |
Carcinoma, Non-Small-Cell Lung/etiology/*genetics | 2 | 40.0 |
Genes, Tumor Suppressor/*genetics | 27 | 8.0 |
Neoplasms, Second Primary/*genetics | 4 | 19.0 |
Radiotherapy/adverse effects | 2 | 5.0 |
Breast Neoplasms/diagnosis/*genetics | 3 | 10.0 |
Cell Transformation, Neoplastic/genetics | 8 | 2.0 |
*Genes, Retinoblastoma | 6 | 5.0 |
*Sequence Deletion | 4 | 1.0 |
Antibiotics, Antineoplastic/pharmacology | 2 | 2.0 |
Carcinoma, Squamous Cell/metabolism | 2 | 3.0 |
Adenocarcinoma/genetics/pathology | 5 | 12.0 |
Carcinoma in Situ/genetics/pathology | 2 | 28.0 |
Carcinoma, Non-Small-Cell Lung/*genetics/pathology | 2 | 7.0 |
Carcinoma, Squamous Cell/genetics/pathology | 2 | 10.0 |
Lung Neoplasms/*genetics/pathology | 6 | 6.0 |
Neoplasm Proteins/*metabolism | 6 | 1.0 |
Receptor, Epidermal Growth Factor/metabolism | 2 | 0.0 |
Brain Neoplasms/*genetics/pathology/secondary | 2 | 50.0 |
Culture Techniques | 3 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
*Gene Expression | 5 | 0.0 |
Carcinoma, Hepatocellular/*genetics | 8 | 9.0 |
Liver Neoplasms/*genetics | 8 | 7.0 |
Lymphoma, B-Cell/drug therapy/*genetics/pathology | 2 | 100.0 |
S Phase/*genetics | 3 | 25.0 |
Germ-Line Mutation/genetics | 2 | 2.0 |
Receptors, Transforming Growth Factor beta/genetics | 3 | 5.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
*Radiation Tolerance | 4 | 7.0 |
S Phase | 5 | 1.0 |
Protein p53/analysis/genetics | 2 | 8.0 |
Cell Culture Techniques | 2 | 0.0 |
Telomerase/genetics | 3 | 18.0 |
*Tumor Cells, Cultured | 3 | 4.0 |
Colorectal Neoplasms/*genetics/pathology | 9 | 10.0 |
Linkage (Genetics) | 6 | 0.0 |
Protein p53/*genetics/immunology | 2 | 66.0 |
Evaluation Studies | 2 | 0.0 |
Neoplasm Recurrence, Local | 7 | 1.0 |
Autoradiography | 2 | 0.0 |
Italy | 2 | 0.0 |
Fluorescence | 3 | 1.0 |
*Genes, APC | 3 | 3.0 |
Electrophoresis/methods | 3 | 3.0 |
Enzyme-Linked Immunosorbent Assay | 5 | 0.0 |
Temperature | 5 | 0.0 |
Skin Neoplasms/genetics | 2 | 6.0 |
Bleomycin/administration & dosage | 2 | 2.0 |
Jews/*genetics | 2 | 1.0 |
Genetic Markers/genetics | 4 | 0.0 |
Syndrome | 7 | 0.0 |
Breast Neoplasms/etiology/*genetics | 3 | 9.0 |
Heterozygote Detection | 3 | 0.0 |
Protein Conformation | 4 | 0.0 |
Adenine | 2 | 3.0 |
Guanine | 2 | 2.0 |
Mutation/*drug effects | 2 | 11.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 3 | 6.0 |
Tamoxifen/*therapeutic use | 2 | 2.0 |
*Chromosome Deletion | 33 | 4.0 |
Colorectal Neoplasms/genetics/*pathology | 2 | 28.0 |
Nuclear Proteins/*genetics | 4 | 0.0 |
*Alpha Particles | 2 | 40.0 |
Transforming Growth Factor beta/metabolism | 2 | 1.0 |
Cell Differentiation/genetics | 3 | 1.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Bladder Neoplasms/genetics | 2 | 16.0 |
In Situ Hybridization, Fluorescence/methods | 5 | 5.0 |
Evolution, Molecular | 2 | 0.0 |
*Genes, BRCA1 | 10 | 1.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
DNA Repair/*drug effects | 2 | 6.0 |
Radiation-Protective Agents/*pharmacology | 2 | 10.0 |
Xeroderma Pigmentosum/*genetics | 2 | 3.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
*Chromosomes, Human, Pair 5 | 3 | 1.0 |
Contig Mapping | 2 | 1.0 |
Stomach Neoplasms/*genetics/pathology | 2 | 4.0 |
Biological Markers/analysis | 2 | 0.0 |
Cytochalasin B/pharmacology | 2 | 2.0 |
DNA Damage/*radiation effects | 3 | 27.0 |
Bone Marrow/pathology | 6 | 1.0 |
Acetyltransferases/*genetics | 2 | 3.0 |
Breast Neoplasms/genetics/pathology | 2 | 5.0 |
Carcinoma/genetics/pathology | 2 | 9.0 |
Colorectal Neoplasms/genetics/pathology | 2 | 11.0 |
Ovarian Neoplasms/genetics/pathology | 2 | 14.0 |
Cell Cycle/*genetics | 5 | 6.0 |
Proto-Oncogenes/genetics | 2 | 6.0 |
Disease Models, Animal | 6 | 0.0 |
Feasibility Studies | 2 | 0.0 |
Genetic Vectors | 4 | 0.0 |
Chromosomes, Human, Pair 13/*genetics | 3 | 4.0 |
Head and Neck Neoplasms/*genetics | 5 | 6.0 |
Kidney Neoplasms/*genetics/pathology | 2 | 2.0 |
Chromosomes, Human, Pair 1/genetics | 7 | 3.0 |
Chromosomes, Human, Pair 11/genetics | 3 | 1.0 |
Chromosomes, Human, Pair 19/genetics | 5 | 4.0 |
Chromosomes, Human, Pair 22/genetics | 2 | 2.0 |
Adenocarcinoma/*genetics | 11 | 7.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
Proteins/*genetics/metabolism | 2 | 0.0 |
Proto-Oncogenes | 8 | 4.0 |
Barrett Esophagus/*genetics/pathology | 3 | 25.0 |
Esophageal Neoplasms/*genetics/pathology | 3 | 9.0 |
Paraffin | 4 | 8.0 |
Microdissection | 2 | 10.0 |
Adenocarcinoma/genetics/secondary | 2 | 50.0 |
Gene Expression Profiling/methods | 2 | 2.0 |
Codon/*genetics | 6 | 9.0 |
Polymorphism, Genetic/*genetics | 7 | 0.0 |
Brain Neoplasms/*genetics/mortality | 2 | 40.0 |
Oncogenes/*genetics | 2 | 2.0 |
Protein p53/*analysis/genetics | 5 | 23.0 |
*Chromosomes, Human, Pair 1 | 4 | 0.0 |
Mouth Neoplasms/*genetics | 4 | 8.0 |
Chromosomes, Human, Pair 17 | 22 | 6.0 |
Precancerous Conditions/*genetics | 5 | 17.0 |
Cloning, Molecular | 8 | 0.0 |
Methotrexate/administration & dosage | 2 | 2.0 |
Protein p53/*analysis | 10 | 5.0 |
Diagnosis, Differential | 4 | 0.0 |
3T3 Cells | 2 | 0.0 |
Membrane Potentials | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 2 | 0.0 |
*Genes, BRCA2 | 3 | 1.0 |
Melanoma/chemistry/pathology/*radiotherapy | 2 | 100.0 |
Proto-Oncogene Proteins c-myc/*analysis | 2 | 15.0 |
Proto-Oncogene Proteins c-raf/*analysis | 2 | 100.0 |
ras Proteins/*analysis | 2 | 33.0 |
Carcinoma, Small Cell/pathology/*radiotherapy | 2 | 100.0 |
Lung Neoplasms/pathology/*radiotherapy | 3 | 60.0 |
Glutathione Transferase/*genetics | 4 | 0.0 |
Leukemia, Myeloid/enzymology/genetics/physiopathology | 2 | 100.0 |
Myelodysplastic Syndromes/enzymology/*genetics/physiopathology | 2 | 100.0 |
Polymorphism, Restriction Fragment Length | 19 | 0.0 |
Germany | 2 | 0.0 |
Lung Neoplasms/etiology | 2 | 18.0 |
Protein p16/*genetics | 10 | 10.0 |
DNA, Neoplasm | 4 | 3.0 |
Papillomavirus, Human/genetics | 3 | 7.0 |
Gallbladder Neoplasms/*genetics/pathology | 2 | 22.0 |
RNA, Messenger/genetics/metabolism | 7 | 0.0 |
Carcinogenicity Tests | 2 | 2.0 |
Mice, Transgenic | 2 | 0.0 |
Glioma/*genetics/pathology | 2 | 6.0 |
*Disease Models, Animal | 2 | 0.0 |
United States | 3 | 0.0 |
Histological Techniques | 2 | 4.0 |
Chromosomes, Human, Pair 11 | 5 | 1.0 |
Chromosomes, Human, Pair 2 | 3 | 1.0 |
DNA, Viral/genetics | 3 | 1.0 |
Papovaviridae Infections | 2 | 33.0 |
Tumor Virus Infections | 3 | 20.0 |
Carcinoma, Basal Cell/genetics | 3 | 25.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Melanoma/genetics | 5 | 14.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
Thyroid Neoplasms/*genetics/pathology | 2 | 6.0 |
Gene Amplification/genetics | 5 | 8.0 |
Carcinoma, Squamous Cell/*genetics/*virology | 2 | 50.0 |
Papillomavirus, Human/*isolation & purification | 2 | 7.0 |
Precancerous Conditions/genetics/pathology | 3 | 16.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
DNA, Neoplasm/analysis/*genetics | 3 | 18.0 |
DNA, Neoplasm/genetics/isolation & purification | 2 | 1.0 |
RNA, Neoplasm/genetics/isolation & purification | 2 | 3.0 |
Cyclin-Dependent Kinases/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
RNA, Messenger/analysis | 7 | 0.0 |
RNA, Neoplasm/analysis | 4 | 1.0 |
Hematologic Neoplasms/*genetics | 2 | 11.0 |
Leukemia, Myeloid, Chronic/*genetics | 3 | 4.0 |
Neoplasm Proteins/analysis | 6 | 1.0 |
Cell Cycle Proteins/*genetics | 2 | 1.0 |
*Muscle Proteins | 2 | 0.0 |
Retinoblastoma Protein/genetics | 2 | 5.0 |
In Situ Hybridization, Fluorescence/*methods | 3 | 3.0 |
Glioblastoma/*genetics | 4 | 5.0 |
Adenocarcinoma/etiology/*genetics | 2 | 25.0 |
Barrett Esophagus/complications/*genetics | 2 | 100.0 |
Carcinoma/*genetics | 5 | 4.0 |
Chromosome Banding/methods | 2 | 28.0 |
Epithelium/pathology | 2 | 1.0 |
Esophagus/pathology | 2 | 12.0 |
Oncogene Proteins, Viral/genetics | 2 | 5.0 |
*Chromosomes, Human, Pair 14 | 2 | 1.0 |
*Chromosomes, Human, Pair 8 | 2 | 0.0 |
*Cell Transformation, Neoplastic | 4 | 0.0 |
*Repressor Proteins | 3 | 0.0 |
Sister Chromatid Exchange | 3 | 6.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Chronic Disease | 4 | 0.0 |
Cosmids | 3 | 0.0 |
DNA Probes | 13 | 1.0 |
DNA, Satellite/genetics | 2 | 1.0 |
Leukemia, B-Cell, Chronic/drug therapy/*genetics/pathology | 2 | 66.0 |
DNA, Satellite/*genetics | 4 | 6.0 |
Myelodysplastic Syndromes/genetics | 3 | 12.0 |
Prostatic Neoplasms/*genetics/pathology | 4 | 4.0 |
Tumor Markers, Biological/analysis | 6 | 0.0 |
In Situ Hybridization/methods | 2 | 1.0 |
Trisomy | 5 | 4.0 |
Barrett Esophagus/*genetics | 2 | 25.0 |
Epithelium | 2 | 3.0 |
Prostatectomy | 2 | 2.0 |
Cell Nucleus/pathology | 2 | 2.0 |
Adenoma/*genetics/pathology | 2 | 7.0 |
Adenocarcinoma/*genetics/metabolism/pathology | 2 | 6.0 |
Colorectal Neoplasms/*genetics/metabolism/pathology | 3 | 15.0 |
Endometrial Neoplasms/*genetics/metabolism | 2 | 22.0 |
Carcinoma, Small Cell/*genetics | 6 | 11.0 |
Retinoblastoma Protein/biosynthesis | 2 | 8.0 |
Antimetabolites, Antineoplastic/pharmacology | 3 | 3.0 |
Cytarabine/pharmacology | 2 | 4.0 |
Glutathione/metabolism | 3 | 1.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
Sequence Analysis | 2 | 0.0 |
Australia | 2 | 1.0 |
*Ovulation | 2 | 10.0 |
Gene Targeting | 2 | 0.0 |
Neoplasms/*genetics/*therapy | 2 | 28.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid/*genetics | 2 | 1.0 |
Carcinoma/genetics/metabolism/*pathology | 2 | 20.0 |
*DNA Replication | 4 | 1.0 |
Leukemia, Myelocytic, Acute/genetics | 2 | 6.0 |
Leukemia, Myeloid, Chronic/genetics | 2 | 8.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Biopsy, Needle | 2 | 0.0 |
Prostate/*pathology | 2 | 8.0 |
Reference Values | 7 | 0.0 |
*Drug Resistance, Neoplasm | 2 | 1.0 |
Fluorouracil/*pharmacology | 2 | 5.0 |
Mitomycin/*pharmacology | 2 | 8.0 |
Cell Survival/*radiation effects | 2 | 12.0 |
Chromosomes, Human/*radiation effects | 2 | 66.0 |
DNA Repair/*radiation effects | 2 | 20.0 |
Cell Cycle Proteins/metabolism | 2 | 0.0 |
Kidney Neoplasms/*genetics | 2 | 0.0 |
Chromosomes, Human, Pair 8 | 6 | 4.0 |
Prostatic Neoplasms/*genetics | 6 | 3.0 |
Chromosomes, Human, Pair 10/genetics | 4 | 5.0 |
Barrett Esophagus/genetics | 2 | 66.0 |
Genes, erbB-2 | 4 | 5.0 |
Interphase | 2 | 1.0 |
Protein p53 | 4 | 16.0 |
Base Pair Mismatch | 3 | 1.0 |
Glioma/*genetics | 4 | 5.0 |
Protein p53/genetics/*physiology | 5 | 14.0 |
Acyltransferases/genetics | 2 | 12.0 |
Forecasting | 5 | 1.0 |
Homeodomain Proteins/genetics | 2 | 0.0 |
Neoplasm Metastasis/genetics | 2 | 4.0 |
Protein p53/drug effects/*genetics | 2 | 100.0 |
*Chromosome Disorders | 6 | 8.0 |
Cell Division/genetics/physiology | 2 | 4.0 |
Colonic Neoplasms/*metabolism/pathology | 2 | 5.0 |
Hela Cells | 2 | 0.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Breast Neoplasms/*genetics/*pathology | 5 | 7.0 |
Apoptosis/genetics/physiology | 2 | 9.0 |
Cell Division/*genetics | 2 | 3.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Genes, Tumor Suppressor/*physiology | 4 | 3.0 |
Neoplasms/genetics | 2 | 1.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics | 2 | 4.0 |
Oncogene Proteins/genetics | 2 | 2.0 |
Lymphoma/*genetics | 2 | 4.0 |
*Chromosomes, Human, Pair 13 | 3 | 1.0 |
Genetic Screening/*methods | 2 | 1.0 |
Conserved Sequence | 4 | 0.0 |
Cyprinodontiformes/*genetics | 2 | 20.0 |
Hybridization, Genetic | 2 | 3.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
*Chromosomes, Human, Pair 18 | 4 | 2.0 |
Hamartoma Syndrome, Multiple/*genetics | 2 | 6.0 |
Cell Differentiation | 5 | 0.0 |
Mouth Mucosa/pathology | 2 | 8.0 |
Transplantation, Heterologous | 6 | 0.0 |
Leukemia, Myeloid/*genetics | 3 | 2.0 |
Genes, Immunoglobulin | 3 | 1.0 |
*Polymerase Chain Reaction | 3 | 1.0 |
Skin/*radiation effects | 2 | 22.0 |
Smoking | 3 | 0.0 |
Glioblastoma/*genetics/pathology | 2 | 8.0 |
Genes, bcl-2/*genetics | 2 | 7.0 |
Ovarian Neoplasms/*genetics/metabolism/pathology | 3 | 10.0 |
DNA, Neoplasm/blood | 2 | 25.0 |
Genes, p53/*genetics/physiology | 3 | 50.0 |
DNA, Neoplasm/isolation & purification | 3 | 10.0 |
Prostatic Neoplasms/chemistry/*genetics/*pathology | 2 | 50.0 |
DNA, Neoplasm/analysis/isolation & purification | 2 | 28.0 |
Translocation, Genetic/*genetics | 3 | 1.0 |
Immunoassay | 2 | 0.0 |
*Monomeric GTP-Binding Proteins | 3 | 6.0 |
Ataxia Telangiectasia/*genetics | 2 | 3.0 |
Proteins/*physiology | 2 | 1.0 |
DNA Damage/*genetics | 2 | 3.0 |
Mammals | 3 | 0.0 |
Mutagenesis/physiology | 2 | 2.0 |
Immunoblotting | 3 | 0.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Exons/*genetics | 5 | 1.0 |
Fibroblasts | 2 | 0.0 |
Hybrid Cells | 7 | 0.0 |
Tumor Stem Cell Assay | 2 | 1.0 |
Stomach Neoplasms/*genetics | 8 | 7.0 |
Protein p16 | 3 | 2.0 |
Adenoma/*genetics/metabolism | 2 | 15.0 |
Proto-Oncogenes/*genetics | 3 | 4.0 |
DNA/isolation & purification | 3 | 2.0 |
Cerebellar Neoplasms/*genetics | 2 | 10.0 |
Medulloblastoma/*genetics | 2 | 9.0 |
Astrocytoma/chemistry/*genetics/pathology | 2 | 100.0 |
Brain Neoplasms/chemistry/*genetics/pathology | 2 | 100.0 |
Apoptosis/physiology | 2 | 0.0 |
Receptors, Progesterone/metabolism | 3 | 1.0 |
Leucovorin/administration & dosage | 2 | 6.0 |
Norway/epidemiology | 2 | 7.0 |
Cattle/*genetics | 2 | 1.0 |
Crosses, Genetic | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 4 | 0.0 |
Cytogenetics | 2 | 2.0 |
Immunologic Techniques | 2 | 0.0 |
Cell Separation | 2 | 0.0 |
*Polymorphism, Single-Stranded Conformational | 3 | 2.0 |
Ovarian Neoplasms/genetics/metabolism/*pathology | 2 | 14.0 |
Drug Resistance, Neoplasm/*genetics | 2 | 2.0 |
DNA | 3 | 0.0 |
South Africa | 3 | 2.0 |
Antibodies, Neoplasm/*blood | 2 | 22.0 |
Ependymoma/*genetics | 2 | 18.0 |
Fluorouracil/administration & dosage | 3 | 2.0 |
Neoplasms/*metabolism | 3 | 3.0 |
Trans-Activators/*genetics | 4 | 1.0 |
*Trisomy | 3 | 2.0 |
*Genes, myc | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
BRCA1 Protein | 2 | 1.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Ultraviolet Rays/adverse effects | 2 | 3.0 |
*Genes, DCC | 2 | 5.0 |
Li-Fraumeni Syndrome/genetics | 3 | 18.0 |
*Gene Rearrangement | 2 | 0.0 |
Repressor Proteins/*genetics | 3 | 1.0 |
Restriction Mapping | 2 | 0.0 |
DNA, Neoplasm/*analysis/genetics | 2 | 13.0 |
Lymphocytes/chemistry | 2 | 3.0 |
Adenomatous Polyposis Coli/genetics | 2 | 6.0 |
Mesocricetus/*genetics | 2 | 22.0 |
Chromosomes, Human, Pair 5 | 4 | 3.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
Chromosomes, Human, Pair 3 | 6 | 3.0 |
Testicular Neoplasms/*genetics/pathology | 2 | 18.0 |
Breast Neoplasms/chemistry/*genetics | 2 | 11.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Regression Analysis | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Sweden | 2 | 0.0 |
Chromosome Mapping/*veterinary | 2 | 5.0 |
Colonic Neoplasms/*genetics | 3 | 3.0 |
Laryngeal Neoplasms/*genetics | 2 | 11.0 |
Testicular Neoplasms/*genetics | 2 | 8.0 |
Chromosomes, Human, Pair 18 | 2 | 1.0 |
Chromosomes, Human, Pair 22 | 2 | 1.0 |
X Chromosome | 2 | 0.0 |
Chromosomes, Human, Pair 7 | 3 | 1.0 |
Cattle | 2 | 0.0 |
Chromosomes, Human, Pair 17/*ultrastructure | 2 | 9.0 |
*Gene Frequency | 2 | 0.0 |
Trans-Activators/genetics | 4 | 1.0 |
*Genetic Vectors | 2 | 0.0 |
Genes, myc/*genetics | 2 | 2.0 |
DNA/blood/genetics | 2 | 3.0 |
Pancreatic Neoplasms/*genetics/pathology | 3 | 7.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Receptor, erbB-2 | 6 | 3.0 |
Soft Tissue Neoplasms/classification/*genetics/pathology | 2 | 100.0 |
Chromosomes, Human, Pair 17/ultrastructure | 2 | 40.0 |
China | 3 | 0.0 |
Chromosomes, Human, Pair 17/*physiology | 3 | 42.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
*Ploidies | 3 | 4.0 |
Phosphoproteins/*genetics | 2 | 0.0 |
Genes, APC | 2 | 2.0 |
Base Pair Mismatch/*genetics | 2 | 3.0 |
Nucleic Acid Heteroduplexes/genetics/metabolism | 2 | 66.0 |
Rectal Neoplasms/*genetics | 2 | 22.0 |
Carcinoma, Hepatocellular/genetics | 2 | 7.0 |
Genetics, Population | 2 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
Lung Neoplasms/secondary | 2 | 2.0 |
p14ARF Protein/*genetics | 2 | 8.0 |
Deoxyribonucleases, Type II Site-Specific/metabolism | 4 | 2.0 |
Lung Neoplasms/genetics | 3 | 5.0 |
Tissue Inhibitor of Metalloproteinase-3/genetics | 2 | 14.0 |
p14ARF Protein/genetics | 5 | 23.0 |
Polydeoxyribonucleotides | 2 | 28.0 |
DNA Mutational Analysis/*standards | 2 | 40.0 |
Electrophoresis, Capillary | 3 | 6.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Reference Standards | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Cell Lineage | 2 | 0.0 |
Tumor Suppressor Proteins/*genetics | 3 | 2.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Keratin/genetics/metabolism | 2 | 28.0 |
DNA/chemistry | 2 | 0.0 |
Trans-Activators/biosynthesis | 2 | 5.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Precancerous Conditions/genetics/*pathology | 2 | 40.0 |
Cell Cycle Proteins/analysis | 2 | 7.0 |
Central Nervous System Neoplasms/*genetics | 2 | 14.0 |
*CpG Islands | 4 | 5.0 |
Tumor Cells, Cultured/drug effects/metabolism/radiation effects | 2 | 18.0 |
Ovarian Neoplasms/*drug therapy/*genetics/pathology | 2 | 100.0 |
O(6)-Methylguanine-DNA Methyltransferase/genetics | 3 | 10.0 |
Breast Neoplasms/genetics | 3 | 1.0 |
G1 Phase/radiation effects | 3 | 37.0 |
BRCA1 Protein/genetics | 2 | 3.0 |
Cell Cycle/physiology | 2 | 0.0 |
Fibroblasts/radiation effects | 2 | 7.0 |
*Trans-Activation (Genetics) | 2 | 0.0 |
